Viridian Therapeutics, Inc./DE
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2022 | $-21.0M | $-21.2M | $179.0K | $4.7M |
| Jun 2022 | $-18.1M | $-18.4M | $292.0K | $4.9M |
| Sep 2022 | $-20.7M | $-20.8M | $95.0K | $4.9M |
| Dec 2022 | $-34.0M | $-34.3M | $231.0K | $5.3M |
| Mar 2023 | $-62.0M | $-62.1M | $115.0K | $15.2M |
| Jun 2023 | $-45.2M | $-45.5M | $331.0K | $12.3M |
| Sep 2023 | $-39.0M | $-39.4M | $404.0K | $13.6M |
| Dec 2023 | $-38.0M | $-38.0M | $48.0K | $26.0M |
| Mar 2024 | $-45.2M | $-45.2M | $0 | $12.7M |
| Jun 2024 | $-46.1M | $-46.2M | $104.0K | $11.8M |
| Sep 2024 | $-67.7M | $-68.0M | $293.0K | $8.7M |
| Dec 2024 | $-73.3M | $-73.4M | $114.0K | $9.0M |
| Mar 2025 | $-92.7M | $-92.7M | $86.0K | $10.2M |
| Jun 2025 | $-75.4M | $-75.4M | $42.0K | $10.8M |
| Sep 2025 | $-84.6M | $-84.7M | $127.0K | $11.3M |
| Dec 2025 | $-23.8M | $-24.0M | $240.0K | $12.0M |
| Mar 2026 | $-119.7M | $-119.7M | $23.0K | $13.4M |
| Jun 2026 | $-105.3M | $-106.6M | $1.3M | $17.0M |